Compare SLDB & ASIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLDB | ASIC |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2017 | 2025 |
| Metric | SLDB | ASIC |
|---|---|---|
| Price | $8.70 | $27.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 4 |
| Target Price | $16.36 | ★ $26.75 |
| AVG Volume (30 Days) | ★ 751.6K | 53.4K |
| Earning Date | 05-12-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.97 | 23.44 |
| EPS | N/A | ★ 1.18 |
| Revenue | $8,094,000.00 | ★ $424,339,000.00 |
| Revenue This Year | N/A | $34.21 |
| Revenue Next Year | N/A | $34.65 |
| P/E Ratio | ★ N/A | $22.99 |
| Revenue Growth | N/A | ★ 23.41 |
| 52 Week Low | $3.79 | $16.35 |
| 52 Week High | $11.45 | $27.90 |
| Indicator | SLDB | ASIC |
|---|---|---|
| Relative Strength Index (RSI) | 45.19 | 60.01 |
| Support Level | $6.25 | $18.56 |
| Resistance Level | $11.45 | $27.22 |
| Average True Range (ATR) | 0.42 | 0.99 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 14.18 | 69.01 |
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
Ategrity Specialty Insurance Co Holdings is a specialty property and casualty insurance holding company focused on the excess and surplus market for small to medium-sized businesses (SMBs) across the United States. Operating through its subsidiaries, the company underwrites small and medium-sized commercial risks across selected industry verticals, including Retail, Real Estate, Hospitality, and Construction. Its operating model uses a technology-driven method to standardize, simplify, and, where appropriate, automate these transactions. The group distributes its products through licensed surplus lines brokers and wholesale agents.